Drug intelligence / Profile preview

ODT-211

Development stage: Unknown
Lead developer: Odyssey Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ODT-211 is an orally bioavailable, potent, and selective small molecule inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), currently under development by Odyssey Therapeutics. STAT6 is a key transcription factor that mediates signaling for interleukin-4 (IL-4) and interleukin-13 (IL-13), which are the primary drivers of Type 2 inflammation. By directly inhibiting STAT6, ODT-211 aims to provide a more targeted approach to treating Th2-mediated diseases compared to upstream cytokine-blocking biologics. The compound is being evaluated for the treatment of various autoimmune and inflammatory conditions, with a primary focus on atopic dermatitis and asthma.

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on ODT-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODT-211.

Explore the full profile